Intensity-modulated radiotherapy for rectal cancer in the UK in 2020

Hanna, C.R., Slevin, F., Appelt, A., Beavon, M., Adams, R. ORCID: https://orcid.org/0000-0003-3915-7243, Arthur, C., Beasley, M., Duffton, A., Gilbert, A., Gollins, S., Harrison, M., Hawkins, M.A., Laws, K., O'Cathail, S., Porcu, P., Robinson, M., Sebag-Montefiore, D., Teo, M., Teoh, S. and Muirhead, R. 2021. Intensity-modulated radiotherapy for rectal cancer in the UK in 2020. Clinical Oncology 33 (4) , pp. 214-223. 10.1016/j.clon.2020.12.011

PDF - Published Version Available under License Creative Commons Attribution. Download (1MB)

Abstract

Aims Preoperative (chemo)radiotherapy followed by total mesorectal excision is the current standard of care for patients with locally advanced rectal cancer. The use of intensity-modulated radiotherapy (IMRT) for rectal cancer is increasing in the UK. However, the extent of IMRT implementation and current practice was not previously known. A national survey was commissioned to investigate the landscape of IMRT use for rectal cancer and to inform the development of national rectal cancer IMRT guidance. Materials and methods A web-based survey was developed by the National Rectal Cancer IMRT Guidance working group in collaboration with the Royal College of Radiologists and disseminated to all UK radiotherapy centres. The survey enquired about the implementation of IMRT with a focus on the following aspects of the workflow: dose fractionation schedules and use of a boost; pre-treatment preparation and simulation; target volume/organ at risk definition; treatment planning and treatment verification. A descriptive statistical analysis was carried out. Results In total, 44 of 63 centres (70%) responded to the survey; 30/44 (68%) and 36/44 (82%) centres currently use IMRT to treat all patients and selected patients with rectal cancer, respectively. There was general agreement concerning several aspects of the IMRT workflow, including patient positioning, use of intravenous contrast and bladder protocols. Greater variation in practice was identified regarding rectal protocols; use of a boost to primary/nodal disease; target volume delineation; organ at risk delineation and dose constraints and treatment verification. Delineation of individual small bowel loops and daily volumetric treatment verification were considered potentially feasible by most centres. Conclusion This survey identified that IMRT is already used to treat rectal cancer in many UK radiotherapy centres, but there is heterogeneity between centres in its implementation and practice. These results have been a valuable aid in framing the recommendations within the new National Rectal Cancer IMRT Guidance.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine Centre for Trials Research (CNTRR)
Publisher:	Elsevier
ISSN:	0936-6555
Date of First Compliant Deposit:	10 May 2021
Date of Acceptance:	11 December 2020
Last Modified:	05 May 2023 22:26
URI:	https://orca.cardiff.ac.uk/id/eprint/141026

Citation Data

Cited 5 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item